Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis

Multiple Sclerosis, Secondary Progressive Clinical Trial

Official title:

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01982942
• Other study ID #: NN102 SPRINT - MS
• Secondary ID: 1U01NS082329-01A
• Status: Completed
• Phase: Phase 2
• Start date: November 2013
• Est. completion date: December 2017

Study information

• Verified date: July 2020
• Source: MediciNova
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety, tolerability and activity of ibudilast administered twice daily over a 96 week period in subjects with primary or secondary progressive multiple sclerosis who are currently untreated with long-term MS disease modifying therapy (DMT) or who are receiving either glatiramer acetate (GA) or interferon beta-1, any formulation (IFNβ-1A [Avonex, Rebif] or IFNβ-1B [Betaseron, Extavia]). Study drug or placebo will be administered to a total of 250 male and female subjects from 21 to 65 years old, inclusive, in two treatment groups. Randomization of subjects will be stratified by disease status (primary progressive multiple sclerosis or secondary progressive multiple sclerosis) and immunomodulating therapy status: current use of immunomodulating therapy or no current use of immunomodulating therapy.

The study will consist of a screening phase (up to 30 days) followed by a treatment phase (96 weeks) and a follow-up visit (1 month post Week 96 visit). Following the screening phase, subjects who continue to meet entry criteria will be randomly assigned to 1 of 2 treatment groups: doses up to ibudilast 100 mg/day or matching-placebo in a 1:1 ratio. Study drug will be administered twice daily (BID), e.g., ibudilast 50 mg or placebo taken in the morning and evening).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 255
• Est. completion date: December 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 65 Years

Eligibility

Inclusion Criteria:

• Written informed consent is obtained and willing and able to comply with the protocol in the opinion of the Investigator.

• Male or female subjects ages 21 to 65, inclusive

• Confirmed diagnosis of SPMS or primary progressive multiple sclerosis (PPMS) according to 2010 International Panel Criteria

• Typical MS lesions on MRI according to Swanton's MRI Criteria (at least one lesion in two or more of the following regions: periventricular, juxtacortical, infratentorial [brainstem/cerebellum], spinal cord)

• EDSS 3.0-6.5, inclusive

• Clinical evidence of disability progression in the preceding two years, as measured by any of the following (excluding progression during clinical relapses):

• worsening overall EDSS of at least 0.5 points (may be assessed retrospectively but cannot be during a clinical relapse) or

• 20% worsening in 25-foot walk (25-FW) or

• 20% worsening in 9-hole peg test (9-HPT) in either hand

• Existing multiple sclerosis pharmacotherapy status may include interferon-beta or glatiramer acetate or none (i.e. untreated).

• Females of child-bearing potential must have a negative serum ß-hCG at screening and must be willing to use appropriate contraception (as defined by the investigator) for the duration of study treatment and 30 days after the last dose of study treatment.

• Males should practice contraception as follows: condom use and contraception by female partner.

• Subject is in good physical health on the basis of medical history, physical examination, and laboratory screening, as defined by the investigator.

• Subject is willing and able to comply with the protocol assessments and visits, in the opinion of the study nurse/coordinator and the Investigator.

Exclusion Criteria:

• Progressive neurological disorder other than SPMS or PPMS

• Relapse and/or systemic corticosteroid steroid treatment for multiple sclerosis within 3 months of screening. Inhaled or topical steroids are allowed.

• Current use of intermittent systemic corticosteroids (i.e., monthly or bimonthly intravenous methylprednisolone)

• Use of oral immunosuppressants (e.g. azathioprine, methotrexate, cyclosporine, teriflunomide [Aubagio®]) within 6 months of screening

• Use of mitoxantrone, natalizumab, or IVIg within 6 months of screening

• Use of fingolimod or dimethyl fumarate [Tecfidera®] within 3 months of screening

• Use of rituximab or other B-cell therapy within 12 months of screening

• Current use of other MS disease-modifying therapies (DMTs) besides glatiramer acetate, IFNß-1 (any formulation), and the above listed medications.

• Current use of cimetidine, cyclosporine, dronedarone, lopinavir, probenecid, quinidine (including Neudexta), ranolazine, rifampin, ritonavir, or tipranavir.

• Clinically significant cardiovascular disease, including myocardial infarct within last 6 months, unstable ischemic heart disease, congestive heart failure or angina

• Resting pulse < 50 bpm, sinoatrial (SA) or atrioventricular (AV) block, uncontrolled hypertension, or QTcF > 450 ms

• Clinically significant pulmonary conditions, including severe chronic obstructive pulmonary disease (COPD), fibrosis, or tuberculosis

• Evidence of acute hepatitis, clinically significant chronic hepatitis, or evidence of clinically significant impaired hepatic function through clinical and laboratory evaluation including ALP > 1.5x ULN; ALT or AST > 2x ULN; GGT > 3x ULN

• Immune system disease (other than multiple sclerosis and autoimmune thyroid disease)

• History of stomach or intestinal surgery or any other condition that could interfere with or is judged by the Investigator to interfere with absorption, distribution, metabolism, or excretion of study drug.

• Any significant laboratory abnormality which, in the opinion of the Investigator, may put the subject at risk and with the following laboratory abnormalities at screening:

• Creatinine: females > 0.95 mg/dL; males > 1.17 mg/dL

• WBCs < 3,000 mm3

• Lymphocytes < 800 mm3

• Platelets < 90,000 mm3

• History of malignancy < 5 years prior to signing the informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.

• History of HIV (human immunodeficiency virus), clinically significant chronic hepatitis, or other active infection.

• Subject currently has a clinically significant medical condition (other than MS) including the following: neurological, psychiatric, metabolic, hepatic, renal, hematological, pulmonary, cardiovascular (including uncontrolled hypertension), gastrointestinal, urological disorder, or central nervous system (CNS) infection that would pose a risk to the subject if they were to participate in the study or that might confound the results of the study.

Note: Active medical conditions that are minor or well-controlled are not exclusionary if, in the judgment of the Investigator, they do not affect risk to the subject or the study results. In cases in which the impact of the condition upon risk to the subject or study results is unclear, the Medical Safety Monitor should be consulted.

• Subjects with moderate to severe depression as determined by the Beck Depression Inventory-Fast Screen (BDI-FS).

• Subject has a history of alcohol or substance abuse (DSM-IV-TR criteria) within 3 months prior to screening or alcohol or substance dependence (DSM-IV-TR criteria) within 12 months prior to screening. The only exceptions include caffeine or nicotine abuse/dependence.

• Subject has poor peripheral venous access that will limit the ability to draw blood as judged by the Investigator.

• Subject is currently participating, or has participated in, a study with an investigational or marketed compound or device within 3 months prior to signing the informed consent.

• Subject is unable to cooperate with any study procedures, unlikely to adhere to the study procedures and keep appointments, in the opinion of the Investigator, or was planning to relocate during the study.

• Subject is unable to undergo MRI imaging because of having an artificial heart valve, metal plate, pin, or other metallic objects (including gun shots or shrapnel) in their body or is unable to complete all the five MRI scans required for this study.

Related Conditions & MeSH terms

• Multiple Sclerosis
• Multiple Sclerosis, Chronic Progressive
• Multiple Sclerosis, Primary Progressive
• Multiple Sclerosis, Secondary Progressive
• Sclerosis

Intervention

Drug:
• ibudilast
Subjects randomly assigned to the ibudilast (MN-166) cohort will receive up to 100 mg/day for 96 weeks.
• Placebo oral capsule
Subjects randomly assigned to the placebo cohort will receive placebo oral capsule for 96 weeks.

Locations

Country	Name	City	State
United States	Emory University	Atlanta	Georgia
United States	University of Alabama at Birmingham	Birmingham	Alabama
United States	Brigham and Women's Hospital	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	Montefiore Medical Center	Bronx	New York
United States	University at Buffalo, The State University of New York	Buffalo	New York
United States	University of Virginia Charlottesville	Charlottesville	Virginia
United States	University of Cincinnati, Department of Neurology	Cincinnati	Ohio
United States	Cleveland Clinic	Cleveland	Ohio
United States	Ohio State University	Columbus	Ohio
United States	University of Texas Southwestern Medical Center	Dallas	Texas
United States	University of California Davis	Davis	California
United States	University of Colorado Denver	Denver	Colorado
United States	Northwestern University	Evanston	Illinois
United States	University of Kansas Medical Center	Kansas City	Kansas
United States	University of California Los Angeles	Los Angeles	California
United States	University of Miami Miller School of Medicine	Miami	Florida
United States	Vanderbilt University	Nashville	Tennessee
United States	Columbia University Medical Center	New York	New York
United States	Cornell Medical College	New York	New York
United States	University of Pittsburgh	Pittsburgh	Pennsylvania
United States	Oregon Health and Science University	Portland	Oregon
United States	University of Rochester	Rochester	New York
United States	Washington University School of Medicine in St Louis	Saint Louis	Missouri
United States	University of Utah	Salt Lake City	Utah
United States	Swedish Medical Center - Seattle	Seattle	Washington
United States	University at Stony Brook, The State University of New York	Stony Brook	New York
United States	University at Upstate, The State University of New York	Syracuse	New York

Sponsors (4)

Lead Sponsor	Collaborator
MediciNova	National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), National Multiple Sclerosis Society

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	New T1 Lesions Since Baseline	New T1 lesions since baseline as measured by least square mean (90% confidence interval).	96 weeks
Primary	Covariate-adjusted Mean Rate of Change in Brain Atrophy Over 96 Weeks as Measured by Brain Parenchymal Fraction (BPF).	To evaluate the activity of ibudilast (100 mg/day) versus placebo at 96 weeks as measured by quantitative magnetic resonance imaging (MRI) analysis for whole brain atrophy using brain parenchymal fraction (BPF), calculated as the ratio of brain parenchymal tissue volume to the total volume contained within the brain surface contour.	96 weeks
Primary	Percentage of Participants With Adverse Events.	Safety Measures: percentage of participants who experienced treatment-emergent adverse events, clinically significant abnormal laboratory and electrocardiogram results.	96 weeks
Secondary	Diffusion Tensor Imaging (DTI) in Descending Pyramidal White Matter Tracts	Diffusion tensor imaging estimates the three-dimensional diffusion of water in brain tissue and has been explored as an outcome in MS.	48 weeks
Secondary	Magnetization Transfer Ratio (MTR) Imaging in Normal-appearing Brain Tissue	A magnetization transfer MRI as a marker of brain myelin content including the cerebral cortex could be useful. MT imaging provides access to the restricted protons, which are located in biologically interesting tissue regions.Cortical and normal appearing grey matter MTR correlates strongly with measures of disability such as the multiple sclerosis functional composite score and can show treatment effects.	96 weeks
Secondary	Retinal Nerve Fiber Layer as Measured by Optical Coherence Tomography (OCT).	Mean retinal nerve fiber layer thickness from baseline measured by Optical coherence tomography (OCT), a non-invasive imaging technique used to obtain high-resolution cross-sectional images of the retina. Increase in thickness is considered improvement.	96 weeks

External Links

•   Related Info